Nitanib ethylsulfonate is a small molecule inhibitor of multi receptor tyrosine kinase and non receptor tyrosine kinase. In 2014, it was approved by FDA for the first time, and was developed and sold by bringer Ingelheim company for the first time. It has been approved by the US Food and Drug Administration (FDA), the European Drug Administration (EMA) and the agency for drugs and medical devices (PMDA) for the treatment of idiopathic pulmonary fibrosis, and by EMA for non-small cell lung cancer.
Manufacturing
